세계 음경암 치료 시장은 2022년 23억 달러에 달했으며, 2023-2030년의 예측 기간 동안 연평균 복합 성장률(CAGR) 5.6%로 성장하여 2030년에는 32억 달러에 달할 것으로 예상됩니다.
음경암 치료 시장은 음경암 발병률 증가, 치료 옵션의 발전, 인지도, 조기 발견, 정부 지원 조치, 의료비 증가, 개인화 된 의료 등의 요인에 의해 주도되고 있습니다.
더 큰 종양학 시장의 일부인 음경암 치료 시장은이 질병으로 진단받은 사람들에게 의약품과 의료 개입을 제공하는 데 중점을 둡니다. 시장에는 수술, 방사선 요법, 화학 요법, 표적 약물, 면역 요법 등 다양한 유형의 치료 옵션이 있습니다.
Frontiers in 2022에 게재된 논문에 따르면, 2020년 세계 음경암 발생률은 36,068건(10만 명당 0.92건)으로 예상되고 있습니다. 그러나 저개발 국가에서는 악성 종양 발생률이 10만 명당 6.1건에 달할 가능성이 있습니다. 편평상피암(SCC)은 가장 흔한 조직형이며 거의 모든 발생에 관여합니다. 근치 수술의 경우, 림프절 전이가 없는 조기 암의 경우 10년 후 전체 생존율(OS)이 96%인 반면, 국소 림프절 전이 및 원격 전이가 있는 환자의 5년 후 전체 생존율은 각각 50%와 12%입니다.
전형적인 화학요법 독성과 완만한 생존율로 인해 세포독성 화학요법은 진행성 병변의 치료와 신보조요법에서 전신 치료에서 중요한 역할을 하고 있습니다. 이는 주로 백금 제제와 탁산계 약물의 병용 요법으로 구성됩니다.
네이처 리뷰 비뇨기과(Nature Reviews Urology) 저널에 게재된 2022년 논문에 따르면, 음경암과 같은 희귀 비뇨생식기암과 관련된 심각한 임상적 격차를 해소하고, 이들 환자의 수명을 연장하기 위해서는 국가 간 치료 및 치료 표준화를 위한 국제적인 협력이 시급히 필요합니다. 국제 협력은 시급합니다. 세계희귀비뇨생식기종양학회(GSRGT)는 이러한 목적을 달성하기 위해 노력하고 있으며, GSRGT의 첫 번째 목표는 희귀종양의 중요한 발생원이지만 이전에는 등록 및 연구 대상에서 제외되었던 개발도상국을 포함시키는 것입니다.
예를 들어, 남미, 아프리카, 인도, 아시아의 3차 의료기관은 북미와 유럽의 학술 센터와 협력하여 세계 각지에서 신속하고 철저한 데이터 수집을 가능하게 하고 있습니다. GSRGT는 환자들에게 증거에 기반한 최선의 치료를 제공하기 위해 각국 의사들이 음경암에 대한 최신의 접근 가능한 정보를 전파할 수 있도록 협력을 촉진할 것입니다. 이는 평판이 좋은 의학 협회와 협력하여 달성됩니다.
화학요법은 빠르게 분열하는 세포를 표적으로 삼기 때문에 암세포에 효과적입니다. 그러나 골수(새로운 혈액 세포가 생성되는 곳), 입과 장의 점막, 모근 등 체내 일부 세포는 분열이 빠릅니다. 이러한 세포는 화학요법에 의해 영향을 받을 수 있고, 이로 인해 좋지 않은 영향을 받을 수 있습니다.
화학요법 약물의 유형, 용량, 투여기간은 부작용에 영향을 미칩니다. 대표적인 부작용으로는 탈모, 구내염, 식욕 감퇴, 구토, 메스꺼움, 변비 또는 설사, 감염 위험 증가(백혈구 감소로 인한), 혈소판 감소로 인한 타박상 및 출혈의 가능성, 피로감 등이 있습니다.
또한, 발암과 종양 진행에 관여하는 분자생물학 및 게놈-에피게놈의 변화가 충분히 이해되지 않은 점과 전향적 임상시험에 환자를 등록하는 데 어려움이 있어 음경암과 같은 희귀종양 치료의 진보를 방해해 왔습니다.
The Global Penile Cancer Treatment Market reached US$ 2.3 billion in 2022 and is expected to reach US$ 3.2 billion by 2030 growing with a CAGR of 5.6% during the forecast period 2023-2030.
The penile cancer treatment market is driven by factors such as increasing incidence of penile cancer, advancements in treatment options, awareness, and early detection, supportive government initiatives, increasing healthcare expenditure, and personalized medicine.
A subset of the larger oncology market, the penile cancer treatment market focuses on offering medicines and medical interventions to people who have been diagnosed with the disease. There are many different types of treatment options available on the market, including surgery, radiation therapy, chemotherapy, targeted medicines, and immunotherapy.
As per the article published in Frontiers in 2022, the anticipated global incidence of penile cancer in 2020 is 36,068 cases (0.92 incidences per 100,000 individuals). However, the incidence of malignant tumors might be up to 6.1 cases/100,000 people in underdeveloped nations. Squamous cell carcinoma (SCC) is the most common histology and is responsible for almost all occurrences. With curative surgery, overall survival (OS) in individuals with early disease without nodal involvement is 96% in 10 years, compared to 50% and 12%, respectively, in 5 years for patients with regional node disease and distant metastatic disease.
With typical chemotherapeutic toxicities and modest survival outcomes, both in the treatment of advanced disease and in the neoadjuvant setting, cytotoxic chemotherapy plays a significant role in systemic treatment. It primarily consists of platinum and taxane combination regimens.
As per the article published in Nature Reviews Urology in 2022, in order to standardize care and therapies across nations, uncover the critical clinical gaps around uncommon genitourinary cancers, such as penile cancer, and increase the life expectancy of these patients, international cooperation is urgently required. Global Society of Rare Genito-urinary Tumors (GSRGT) seeks to achieve these objectives. The initial goal of the GSRGT is to incorporate developing nations, which are a significant source of uncommon tumors but were previously excluded from registries and studies.
For instance, tertiary care facilities in South America, Africa, India, and Asia collaborate with academic centers in Europe and North America to enable rapid and thorough data recovery from all corners of the world. In order to provide patients with the best available evidence-based treatments, GSRGT will encourage cooperation between doctors from various nations in order to spread up-to-date and easily accessible information about penile cancer. This will be accomplished through working with reputable medical societies.
Chemotherapy medications target rapidly dividing cells, which is why they are effective against cancer cells. However, some cells in the body divide quickly, including those in the bone marrow (where new blood cells are produced), the lining of the mouth and intestines, and the hair follicles. These cells can be impacted by chemotherapy, which may have unfavorable repercussions.
The type, dosage, and duration of the chemotherapy medications affect the adverse effects. Typical negative consequences include loss of hair mouth ulcers decrease in appetite, vomiting, nauseous, constipation or diarrhea, infection risk is increased (because of decreased white blood cell levels), and low blood platelet counts can cause easy bruising or bleeding as well as fatigue.
In addition, the lack of a thorough understanding of the molecular biology and genomic and epigenomic alterations involved in carcinogenesis and tumor progression, as well as the difficulty in enrolling patients for prospective clinical trials, have always hampered advances in the treatment of rare tumors like penile cancer.
The global penile cancer treatment market is segmented based on type, treatment, end-user and region.
The chemotherapy segment accounted for the highest market stake accounting for approximately 37.6% of the penile cancer treatment market in 2022. Cancer-curing medications are administered orally or by venous injections during systemic chemotherapy. These medications reach cancer cells all around the body via the bloodstream. Penile tumors that have migrated to distant organs or lymph nodes are the most common candidates for this treatment. Before surgery, tumors may be shrunk with chemotherapy to make them easier to remove.
Chemotherapy is administered by doctors in cycles, with a rest interval following each cycle to allow the body to heal. Chemotherapy cycles typically last 3 to 4 weeks. Cisplatin, Fluorouracil (5-FU), Paclitaxel (Taxol), Ifosfamide (Ifex), Mitomycin C, and Capecitabine (Xeloda) are a few of the medications used to treat penile cancer. In order to treat penile cancer that has progressed to lymph nodes or other organs, 2 or more of these medications are frequently combined. Cisplatin plus 5-FU is one of the most often used combos.
North America is estimated to hold around 1/3rd of the total market share throughout the forecast period. The active major players are driving the market in the North American region. Penile cancer is a rare form of cancer, especially in developed countries. Over 2000 new cases are reported annually in the United States, with rates of fewer than 1 per 100,000 men. However, there is a much higher occurrence in underdeveloped countries, where there is also a lack of therapeutic knowledge and access to care, which contributes to an unmet clinical need. The link with human papillomavirus infection, which may be present in as many as 50% of all penile carcinomas, is the most notable risk factor for penile cancer.
Older men are more likely to get penile cancer, and the incidence rate continually rises with age. Penile cancer most frequently affects men between the ages of 50 and 70, with a mean age of 67 in the United States of America.
The major global players in the market include: Merck, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb, Roche, Novartis, Shanghai Junshi Biosciences Co., Ltd., Innovent Biologics, Jiangsu Hengrui Medicine Co., Ltd., and BeiGene Ltd. among others.
The Russia-Ukraine war may affect the penile cancer treatment market due to a lack of facilities being impacted during times of geopolitical instability and economic uncertainty. Healthcare workers are frequently displaced, medical supply lines are disrupted, and healthcare facilities are damaged during armed conflicts. The impacted people in Russia and Ukraine have less access to cancer detection and treatment options as a result.
Artificial intelligence (AI) is increasingly being used in the penile cancer treatment market to improve various aspects of data analysis. AI can help oncologists create individualised treatment plans for patients with penile cancer. AI can make therapeutic recommendations that are specific to each patient by examining patient data, medical history, and the results of similar instances.
The global penile cancer treatment market report would provide approximately 69 tables, 71 figures, and 195 Pages.
LIST NOT EXHAUSTIVE